Unfortunately it looks like the numerous recent additions/removals to Starpharma’s board of directors (including a new CFO/Secretary) has made no difference to the DNA of Starpharma.
Unfortunately I cannot see change ever occurring whilst this 17 year CEO and cheque-collecting Chairman remain firmly in control.
When did the DEP-Docetaxel monotherapy trial actually finish recruiting and treatment? We do not know, because the market was not informed. There was no announcement. The news was just added flippantly to todays Quarterly Report.
In my opinion, a company that operates like this is just not investment grade.
SPL Price at posting:
48.0¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)